Clinical Trials

Cancer Type

State

Phase

Treatment

Inhibitor

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (TroFuse-007)

NCT 06170788 Brief Summary The primary objective of the study is to…

Read more arrow_forward

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (TroFuse-005)

NCT 06132958 Brief Summary Researchers are looking for new ways to treat…

Read more arrow_forward

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT 06074588 Brief Summary The purpose of this study is to evaluate…

Read more arrow_forward

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT 06074588 Brief Summary The purpose of this study is to evaluate…

Read more arrow_forward

Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT 06697301 Brief Summary The study is for patients with advanced melanoma…

Read more arrow_forward

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT 04262466 Brief Summary Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell…

Read more arrow_forward

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

NCT 04663347 Brief Summary The purpose of this trial is to measure…

Read more arrow_forward

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)

NCT 05544552 Brief Summary The purpose of this study is to…

Read more arrow_forward

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

NCT 04450732 Brief Summary Phase I Dose Finding Study for GQ1001 in…

Read more arrow_forward

Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (INVISE)

NCT 06539338 Brief Summary The purpose of this first-in-human study is to…

Read more arrow_forward

Knowledge Base

Cancer Types Cancer Services Health Professionals Clinical Trials

How we help you

Our support knows no limits, which means we do whatever it takes to be there for all you need.

How we help you View the Rare Cancer Support Guide

Can’t find what you’re looking for?

We have a friendly team available to chat about any questions you may have, or just to lend an ear if you’re having a tough time.

Call 1800 257 600 Have us call you